Abstract
AimThe aim of this investigation is to detect potential inhibitor for visceral leishmaniasis through computational analysis. BackgroundLeishmaniasis is categorized as a vector born pathogenic infection prevalent in tropical, subtropical, and in Mediterranean zones spread by intra-macrophage protozoa. The clinical syndrome of leishmaniasis is divided into the following type’s namely cutaneous leishmaniasis, mucocutaneous leishmaniasis, visceral leishmaniasis, and dermal leishmaniasis. Trypanothione synthetase is a key enzyme involving in glutathione biosynthesis as well as hydrolysis. Trypanothione is one of the promising drug targets for parasites. Parasites are inimitable with concern to their dependence on trypanothione to regulate intracellular thiol-redox balance in fighting against oxidative stress and biochemical anxiety. However, trypanothione synthetase was presumed as the target therapeutic alternate in VL therapy. ObjectiveThe important objective of this current investigation is to identify or analyze the potential inhibitor for V. leishmaniasis through computational approaches which include virtual screening, molecular docking, ADME prediction, and molecular dynamic simulation. MethodsAn investigation was performed to develop a 3D protein structure, using computational screening among associated similar structured proteins from popular compound database banks such as Specs, Maybridge, and Enamine, to detect novel staging with a series of validation for emerging innovative drugs molecules. Modeled protein ligand complex was further analyzed to know the binding ability of the complex. Molecular dynamics were performed to ascertain its stability at 50 ns. ResultsTrypanothione synthetase overall ability in the outcome of series of analysis. Among three database compounds screened, the compound from the Specs database exhibited the better protein-ligand docking scores and fulfilled the drug-like properties through ADMET analysis, and the docked complexes had better stability throughout the simulation. Besides, the other two database leads fulfilled the pharmacological properties, and the complexes were stable in the simulation. ConclusionBy analyzing the various compounds from different databases, we concluded that the Specs database compound exhibits potential activity against the target protein and is considered a promising inhibitor for trypanothione synthetase.
Highlights
Visceral leishmaniasis (VL) is a dangerous destructive syndrome, among different kinds of leishmaniasis
By analyzing the various compounds from different databases, we concluded that the Specs database compound exhibits potential activity against the target protein and is considered a promising inhibitor for trypanothione synthetase
The virtual screening which is based on molecular docking is one of the essential factors for finding the potential inhibitor for leishmaniasis, which helps to find out the protein-ligand interactions and protein-protein interactions which were monitored by an array of intermolecular interactions [23]
Summary
Visceral leishmaniasis (VL) is a dangerous destructive syndrome, among different kinds of leishmaniasis. Unique clinical features of VL includes lengthen fever, a sudden weight loss, liver inflammation, and increased signs of anemia, resulting in more complications due to the following cosmopolitan infections It intruded into the microphages and multiplied in it, to attack and target reticuloendothelial systems covering the liver, spleen, and bone marrows [2]. Trypanothione pathway is absent in humans but necessary for the survival of parasites; they are categorized as antileishmanial drug target [7]. Under these conditions, TryS remains the most promising target because leishmania is a low-abundance, essential enzyme because without any homologs of humans. Trypanothione synthetase was presumed as the target therapeutic alternate in VL therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.